Episenta - new formulation of sodium valproate

Beacon Pharmaceuticals has launched Episenta (sodium valproate) capsules and sachets, indicated for the treatment of all forms of epilepsy.

Episenta capsules and sachets contain many minitablets, each of which is a prolonged-delivery unit, giving the option of once-a-day treatment. The minitablets can be sprinkled on to soft foods or taken with drinks.

The recommended dose for adults should start at 600mg daily increasing by 150–300mg at three-day intervals until control is achieved. This is generally within the dosage range of 1,000mg to 2,000mg per day (ie, 20–30mg/kg body weight daily). Where adequate control is not achieved within this range, the dose may be further increased to a maximum of 2,500mg per day.

Episenta solution for injection was launched earlier this year. This is a ready-to-use solution of sodium valproate (100mg/ml), in contrast to the other currently available preparation, which is available as a powder for reconstitution (95mg/mL when reconstituted due to displacement). Episenta solution for injection is available as 300mg/3ml ampoules in packs of five.

Further information: Beacon 01892 600930

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more